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Background: Catechol-O-methyltransferase (COMT) is one of the most important enzymes involved in estrogen
metabolism and its functional genetic polymorphisms may be associated with breast cancer (BC) risk. Many
epidemiological studies have been conducted to explore the association between the COMT Val158Met
polymorphism and breast cancer risk. However, the results remain inconclusive. In order to derive a more precise
estimation of this relationship, a large meta-analysis was performed in this study.
Methods: Systematic searches of the PubMed, Embase and Cochrane Library were performed. Crude odds ratios
(ORs) with 95% confidence intervals (CIs) were calculated to estimate the strength of the association.
Results: A total of 56 studies including 34,358 breast cancer cases and 45,429 controls were included. Overall, no
significant associations between the COMT Val158Met polymorphism and breast cancer risk were found for LL
versus HH, HL versus HH, LL versus HL, recessive model LL versus HL+HH, and dominant model LL+HL versus HH.
In subgroup analysis by ethnicity, source of controls, and menopausal status, there was still no significant
association detected in any of the genetic models.
Conclusion: Our meta-analysis results suggest that the COMT Val158Met polymorphism may not contribute to
breast cancer susceptibility.
Virtual slides: The virtual slides(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs4806123577708417
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Breast cancer is one of the most frequently occurring
cancer and cancer-related deaths are highly prevalent
worldwide, which has become a major public health
challenge [1]. The mechanism of developing breast can-
cer is still unclear. It has been widely accepted that ex-
posure to circulating estrogen may be important in the
development of breast cancer. Since estrogen biosyn-
thesis and metabolism consist of many translation and
transcription steps, the genes involved in these processes
may contribute to the level of estrogen and thereby* Correspondence: lis8858@126.com; zhaojinmin@126.com
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reproduction in any medium, provided the orinfluence the susceptibility to breast cancer. Among the
genes identified, BRCA1 and BRCA2 mutations have
been reported to be associated with a dominantly
inherited increased risk of the disease. However, they
only account for about 5% of breast cancer occur-
rences [2]. This fact leaves the possibility that low-
penetrance genetic factors are likely to explain most of
disease cases.
Catechol-O-methyltransferase (COMT) is an import-
ant phase II enzyme involved in the conjugation and in-
activation of catechol estrogens [3]. COMT is expressed
at high levels in a variety of human tissues including
liver, kidney, breast, and red blood cells [4]. The COMT
gene is located on chromosome 22q11 [5]. A G to A
transition in the COMT gene results in valine to methio-
nine amino acid change in codon 108/158 in the cyto-
solic/membrane-bound form of the protein. This amino. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in enzymatic activity [6,7]. Since the variant form (Met)
has been associated with decreased activity of the COMT
compared with the wildtype (Val), these two forms
are represented as COMT-L allele and COMT-H allele,
respectively. It has been hypothesized that the indivi-
duals who inherit the low activity COMT-L gene may be
at increased risk for breast cancer because of an
increased accumulation of the catechol estrogen inter-
mediates [8-11].
The role of COMT Val158Met polymorphism in the
development of breast cancer has been investigated in
the past decade, with conflicting results. Several studies
have previously suggested an association between the
COMT Val158Met polymorphism and an increased risk
of breast caner [12-14]. However, other studies have
failed to confirm such an association [15,16]. Moreover,
two meta-analyses investigating the same hypothesis
[17,18], quite similar in methods and performed almost
at the same time, yielded different conclusions. The
exact relationship between genetic polymorphisms of
COMT Val158Met and susceptibility to breast cancer
has not been entirely established. To clarify the effect of
COMT Val158Met on the risk of breast cancer, our




Electronic databases PubMed (http://www.ncbi.nlm.nih.
gov/pubmed/), Embase (http://www.embase.com/) and
Cochrane Library (http://www.thecochranelibrary.com/
view/0/index.html) were used to search for all genetic
association studies evaluating the COMT Val158Met
polymorphism and breast cancer risk up to February
2012, the search strategy was based on combinations
of “Breast cancer”, “Catechol-O-methyltransferase”,
“COMT”, “polymorphism”, and “mutation”. No lan-
guage or country restrictions were applied. All eligible
studies were retrieved, and their bibliographies were
checked for other relevant publications. Review articles
and bibliographies of other relevant studies identified
were searched by hand to find additional eligible stud-
ies. When multiple publications reported on the same
or overlapping data, we chose the most recent or lar-
gest population. When a study reported the results on
different subpopulations, we treated it as separate
studies in the meta-analysis.
Selection criteria
Studies included in our meta-analysis had to meet the
following inclusion criteria: (1) evaluate the association
between COMT Val108/158Met polymorphism and
breast cancer risk; (2) case–control design; (3) sufficientdata for estimating an odds ratio (OR) with 95% confi-
dence interval (CI); and (4) studies with full text articles.
Studies were excluded if one of the following existed: (1)
no control population; and (2) duplicate of previous
publication.
Data extraction
Information was carefully extracted from all eligible
publications by two investigators (Xue Qin and Qiliu
Peng) independently according to the inclusion cri-
teria listed above. For conflicting evaluation, an agree-
ment was reached following discussion during a
consensus meeting with a third reviewer (Aiping Qin).
For each study, the following information were col-
lected: First author’s name, year of publication, coun-
try, ethnicity of the studied population, total numbers
of cases and controls, breast cancer diagnosis criteria,
matching criteria, genotyping method, menopausal sta-
tus, sources of the control population, quality control
of genotyping and P value for control population in
Hardy–Weinberg equilibrium (HWE). We did not de-
fine any minimum number of patients to include in
our meta-analysis.
Statistical analysis
Crude odds ratios (ORs) together with their correspond-
ing 95% CIs were used to assess the strength of associ-
ation between the COMT Val158Met polymorphism and
breast cancer risk. The pooled ORs were performed for
co-dominant model (LL vs. HH, HL vs. HH, and LL vs.
HL), dominant model (LL+ HL vs. HH), and recessive
model (LL vs. HL+HH), respectively. Departure from the
Hardy–Weinberg equilibrium for the control group in
each study was assessed using a web-based program
(http://ihg2.helmholtz-muenchen.de/cgibin/hw/hwa1.pl).
In subgroup analysis, we evaluated the effect of COMT
Val108/158Met polymorphism on the susceptibility of BC in
different population stratified by ethnicity (Caucasian, Asian,
and Mixed/other), menopausal status (Pre-, and Post-) and
sources of the control population (HB, PB, and FB).
For each genetic comparison, a chi-square-based Q-
statistic test was used to evaluate the between-study het-
erogeneity of the studies. If P < 0.10, the between-study
heterogeneity was considered to be significant, we chose
the random-effects model to calculate the OR. Other-
wise, when P ≥ 0.10, the between study heterogeneity
was not significant, then the fixed effects model was
used. We also measured the effect of heterogeneity using
a quantitative measure, I2 = 100% × (Q – df )/Q [19].
The I statistic measures the degree of inconsistency in
the studies by calculating what percentage of the total
variation across studies is due to heterogeneity rather
than by chance [20]. Finally, the overall or pooled esti-
mate of risk (OR) was calculated by a random effects
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(Mantel–Haenszel) according to the presence (P < 0.10
or I2 > 50%) or absence (P ≥ 0.10 and I2 ≤ 50%) of het-
erogeneity, respectively.
Cumulative meta-analysis was conducted to identify
the influence of the first published study on the subse-
quent publications, and the evolution of the combined
estimates over time according to the ascending date of
publication. To identify potentially influential studies,
sensitivity analysis was also performed by excluding the
studies without definite diagnostic criteria, the studies
without quality control when genotyping and the studies
whose genotype frequencies in control populations exhib-
ited significant deviation from the Hardy–Weinberg equi-
librium (HWE), given that the deviation may denote bias.
The funnel plots and Egger regression asymmetry test
were used to assess publication bias. Egger’s test can
detect funnel plot asymmetry by determining whether
the intercept deviates significantly from zero in a re-
gression of the standardized effect estimates against
their precision. A T test was performed to determine
the significance of the asymmetry. An asymmetric
plot suggested possible publication bias (P ≥ 0.05 sug-
gests no bias). All analyses were performed using




According to our search criteria, 61 studies relevant to
the role of COMT Val158Met polymorphism on BC risk
were identified. Ten of these articles were excluded: one
of these articles was a review [21], four were overlapped
subjects [22-25], four did not provide allele or genotyp-
ing data [26-29], and one was a study concerned with
COMT 1222 G>A polymorphism [30]. Manual search of
references cited in the published studies did not reveal
any additional articles. As a result, a total of 51 relevant
studies met the inclusion criteria for the meta-analysis
[9-16,31-73]. Among them, five of the eligible studies
contained data on two different ethnic groups, and we
treated them independently [31,51,56,60,69]. Therefore,
a total of 56 separate comparisons consisting of 34,358
BC patients and 45,429 controls were included in our
meta-analysis. The characteristics of the 56 case–control
comparisons selected for determining the relationship
between COMT Val108/158Met polymorphism and risk
of BC are summarized in Table 1. These 56 comparisons
were consisted of 33 Caucasian samples, 18 Asian popu-
lations and 5 mixed/other populations. Thirty of the
studies were population-based case–control studies and
20 were hospital-based studies, four of these studies
[44,54,60,69] presented COMT Val158Met polymorph-
ism genotype distributions according to family history(familial-based breast cancer). There were 22 compari-
sons concerned with COMT Val158Met polymorphism
and premenopausal BC patients and 27 comparisons
concerned with COMT Val158Met polymorphism and
postmenopausal BC patients (see Table 1). Seventy-one
percent (40/56) studies in the present meta-analysis used
the golden criteria of “histologically confirmed” or
“pathologically conformed” as BC diagnosis. Eighty-
two (46/56) percent of the control populations matched
to BC patients with age and 52% (29/56) studies used
the classic PCR-RFLP assay to genotype the COMT
Val158Met polymorphism, about 52% (29/56) of the
case–control studies included mentioned the quality
control when genotyping. The genotype frequencies of
control group in 3 studies were not consistent with
HWE [33,41,70]. We could not calculate the P value of
HWE in two studies [66,73] because they only provided
data with dominant model. To remove possible HWE
stratification, for each analysis involving any of these 5
studies, sensitivity analysis would be carried out by ex-
cluding the studies the genotype frequencies for control
group of which deviate from HWE and the studies
whose P value of HWE in the control group could not
be calculated.
Quantitative synthesis of data
The pooled ORs along with their 95% CIs and the
results of the heterogeneity test are presented in detail
in Table 2. Overall, no significant associations between
COMT Val158Met polymorphism and breast cancer sus-
ceptibility were observed in all genetic models when all
the eligible studies were pooled into the meta-analysis.
No significant associations were found for LL versus HH
(OR = 0.999, 95% CI 0.0.925–1.078; I2 =55.0 and P =
0.000 for heterogeneity), HL versus HH (OR = 1.005,
95% CI 0.959–1.052; I2 =27.1 and P = 0.038 for hetero-
geneity), LL versus HL (OR = 0.983, 95% CI 0.926–
1.045; I2 =44.4 and P = 0.000 for heterogeneity),
recessive model LL versus HL+HH (OR = 0.988, 95% CI
0.929–1.050; I2 =51.3 and P = 0.000 for heterogeneity)
and dominant model LL+HL versus HH (OR = 1.001,
95% CI 0.954–1.051; I2 =41.0 and P = 0.001 for hetero-
geneity). Next, the effect of COMT Val158Met poly-
morphism on breast cancer risk was evaluated according
to ethnicity, menopausal status (Figure 1; Figure 2) and
sources of controls. Similarly, no significant association
was found in any of the genetic models. We further
conducted a meta-analysis after the five studies
[33,41,66,70,73] whose genotype frequencies significantly
deviated from HWE or whose P values of HWE in the
control population unable to be calculated were
excluded. The results were not materially changed in
any genetic models. Sensitivity analysis by excluding the
studies without definite diagnostic criteria and the
Table 1 General characteristics of individual studies in the meta-analysis of COMT Val158Met polymorphism and
breast cancer















Lavigne 1997 America Caucasian 113/114 NR Age, race PCR-RFLP Pre-, Post- HB NR 0.862
Thompson
1998
America Caucasian 281/289 Histologically
confirmed
Age, region PCR-RFLP Pre-, Post- PB NR 0.522
Millikana
1998
America Caucasian 389/379 Histologically
confirmed
Age, race PCR-RFLP Pre-, Post- PB Yes 0.916
Millikanb
1998
America Mixed/other 265/263 Histologically
confirmed
Age, race PCR-RFLP Pre-, Post- PB Yes 0.838
Huang
1999
China Asian 118/125 Pathologically
conformed
NR PCR-RFLP Pre-, Post- HB NR 0.612
Goodman
2001
America Caucasian 112/113 Histologically
confirmed
Age, race PCR-RFLP Mixed PB Yes 0.788
Mitrunen
2001
Finland Caucasian 481/480 Histologically
confirmed
NR PCR-RFLP Pre-, Post- PB NR 0.921
Yim 2001 Korea Asian 163/163 Histopathologically
confirmed
Age PCR-RFLP Pre-, Post- HB Yes 0.004
Jungestrom
2001
Sweden Caucasian 126/117 NR Age PCR-RFLP Pre- HB NR 0.209
Hamajima
2001
Japan Asian 150/165 Histologically
confirmed
NR PCR-RFLP Pre-, Post- HB NR 0.079
Kocabas
2002
Turkey Caucasian 84/103 Histologically
confirmed
Age PCR-RFLP Pre-, Post- HB NR 0.227
Comings
2003
America Caucasian 67/145 NR Region PCR-RFLP Post- PB NR 0.335
Wedren 2003 Sweden Caucasian 1490/1340 NR Age DASH Post- PB Yes 0.772
Wu 2003 America Asian 589/562 NR Age, race TaqMan Mixed PB NR 0.646
Tan 2003 China Asian 250/250 Histopathologically
confirmed
Age PCR-RFLP Pre-, Post- HB NR 0.174
Sazci 2004 Turkey Caucasian 130/224 Histopathologically
confirmed
Age PCR-RFLP Pre- PB NR 0.000
Dunning
2004
UK Caucasian 2850/1908 NR Age, region TaqMan Post- PB Yes 0.232
Hefler 2004 Austria Caucasian 391/1698 Histologically
confirmed
Age, region Sequencing Mixed HB Yes 0.577
Ahsan 2004 America Caucasian 313/262 Histopathologically
confirmed
Age LP Mixed FB Yes 0.108
Modugno
2005
America Caucasian 250/3950 Histopathologically
confirmed
NR TaqMan Post- PB NR 0.391
Lin 2005 China Asian 99/366 Pathologically
conformed
Age, region PCR-RFLP Mixed PB Yes 0.972
Lin 2005 China Asian 87/341 Pathologically
conformed
Age, region PCR-RFLP Mixed PB Yes 0.393
Marchand
2005
America Mixed/other 1339/1370 NR Age PCR-RFLP Post- PB NR 0.109
Wen 2005 China Asian 1120/1191 Pathologically
conformed
Age PCR-RFLP Pre-, post- PB Yes 0.698
Cheng 2005 China Asian 496/740 Pathologically
conformed
Age NR Mixed HB Yes 0.006
Gaudeta 2006 America Caucasian 1048/1092 Pathologically
conformed
Age MALDI-TOF Pre-, post- PB Yes 0.853
Gaudetb 2006 Poland Caucasian 1983/2279 Histopathologically
confirmed
Age TaqMan Mixed PB Yes 0.525
Gallicchio
2006
America Caucasian 81/1251 Pathologically
conformed
NR TaqMan Mixed PB NR 0.440
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Table 1 General characteristics of individual studies in the meta-analysis of COMT Val158Met polymorphism and
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Chang 2006 China Asian 189/321 Histologically
confirmed
Age PCR-RFLP Mixed HB NR 0.068
Onay 2006 Canada Caucasian 398/372 Pathologically
conformed
Age TaqMan Pre- FB Yes 0.283
Pharoah 2007 UK Caucasian 2176/2012 NR NR TaqMan Mixed PB NR 0.287
Ralpha 2007 America Caucasian 1626/3286 NR Age TaqMan Pre-, post- HB Yes 0.758
Ralphb 2007 America Caucasian 500/1005 NR Age TaqMan Pre-, post- HB Yes 0.549
Akisik 2007 Turkey Caucasian 114/108 NR Age PCR-RFLP Mixed NR NR 0.966
Hu 2007 China Asian 112/110 Pathologically
conformed
Age Sequencing Pre-, post- HB NR 0.252
Takata 2007 America Mixed/other 325/250 Mammographically
examed
Age PCR-RFLP Pre-, post- PB NR 0.104
Onaya 2008 Canada Caucasian 1217/714 Pathologically
conformed
Age TaqMan Mixed FB Yes 0.832
Onayb 2008 Finland Caucasian 708/549 Pathologically
conformed
Age TaqMan Mixed FB Yes 0.676
Justenhoven
2008
Germany Caucasian 606/622 NR Age MALDI-TOF MS Mixed PB Yes 0.654
He 2009 America Caucasian 1212/1683 Pathologically
conformed
Age TaqMan Mixed HB Yes 0.850
Reding 2009 America Caucasian 891/878 NR Age TaqMan post- PB Yes 0.606
GENICA 2009 Germany Caucasian 3144/5481 Histologically
conformed
Age, region MALDI-TOF MS post- PB Yes 0.094
Yadav 2009 India Asian 154/166 NR Region PCR-RFLP Pre-, post- HB NR 0.570
Shrubsole
2009
China Asian 1093/1169 Pathologically
conformed
Age PCR-RFLP Pre-, post- PB Yes —
Sangrajrang
2009
Thailand Asian 565/486 Histologically
conformed
NR TaqMan Mixed HB Yes 0.610




PCR-RFLP Pre-, post- HB NR 0.669
Syamalaa
2010
India Asian 219/367 Histologically
conformed
Age PCR-RFLP Mixed PB NR 0.183
Syamalab
2010
India Asian 140/367 Histologically
conformed
Age PCR-RFLP Mixed FB NR 0.183
Peterson
2010
America Caucasian 1584/1416 Pathologically
conformed
Age TaqMan Mixed PB Yes 0.026
Delort 2010 France Caucasian 910/1000 Pathologically
conformed
Age TaqMan Mixed PB Yes 0.230
Wang 2011 China Asian 400/400 Histopathologically
conformed
Age Sequencing Pre-, post- PB Yes 0.389
Naushad
2011
India Asian 212/233 Histopathologically
conformed
NR PCR-RFLP Mixed HB NR 0.201
Cribb 2011 Canada Caucasian 207/621 Histopathologically
conformed
Age PCR-RFLP Mixed HB NR 0.208
Cerne 2011 Slovenia Caucasian 530/270 NR Age TaqMan post- HB Yes 0.903
Lajin 2011 Syria Mixed/other 135/107 Pathologically
conformed
Age PCR-RFLP Pre-, post- PB NR 0.887
Santos 2011 Brazil Mixed/other 62/62 Pathologically
conformed
Age PCR-RFLP Pre-, post- PB NR —
PB Population-based FB family-based, HB hospital-based, HWE Hardy–Weinberg equilibrium, NR not reported, Pre- premenopausal, Post- postmenopausal,
PCR-RFLP PCR-based restriction fragment length polymorphism, MALDI-TOF MS matrix assisted laser desorption/ionization time-of-flight mass spectrometry,
LP Luorescence polarization.
a, b They were two different case–control studies in one publication.
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Table 2 Meta-analysis of the COMT Val158Met polymorphism on BC susceptibility
Comparison Population Sample size No. of studies Test of association Mode Test of heterogeneity
Case Control OR 95% CI P value χ2 P value I2
LL vs. HH Overall 17,223 23,069 54 0.999 0.925-1.078 0.976 R 117.76 0.000 55.0
Caucasian 12,942 18,066 32 0.960 0.897-1.028 0.240 R 49.28 0.020 37.1
Asian 3,009 3,790 17 1.243 0.942-1.641 0.125 R 54.34 0.000 70.6
Pre- 2,095 2,523 21 1.049 0.825-1.334 0.697 R 48.22 0.000 58.5
Post- 7,215 10,138 26 0.982 0.875-1.102 0.757 R 45.40 0.008 44.9
PB 17,223 23,069 28 0.999 0.925-1.078 0.381 R 48.00 0.008 43.7
HB 3,800 6,169 20 1.151 0.946-1.402 0.160 R 58.86 0.000 67.7
FB 1,351 1,140 5 0.848 0.712-1.010 0.064 F 4.43 0.351 9.7
HL vs. HH Overall 22,589 33,568 54 1.005 0.959-1.052 0.845 R 72.70 0.038 27.1
Caucasian 19,059 25,912 32 0.999 0.958-1.042 0.968 F 30.14 0.510 0.0
Asian 4,525 5,781 17 1.052 0.923-1.200 0.448 R 36.85 0.002 56.6
Pre- 3,204 3,877 21 0.962 0.871-1.062 0.440 F 27.59 0.119 27.5
Post- 10,480 14,476 26 1.009 0.954-1.067 0.762 F 33.83 0.112 26.1
PB 17,648 22,679 28 0.987 0.945-1.030 0.547 F 3.60 0.463 0.0
HB 5,751 9,128 20 1.075 0.966-1.195 0.187 R 33.89 0.019 43.9
FB 2,102 1,674 5 0.950 0.824-1.094 0.476 F 30.98 0.272 12.9
LL vs. HL Overall 23,594 31,759 54 0.983 0.926-1.045 0.586 R 95.26 0.000 44.4
Caucasian 19,579 27,208 32 0.954 0.911-1.001 0.055 F 36.02 0.245 13.9
Asian 2,538 3,135 17 1.170 0.895-1.528 0.251 R 49.83 0.000 67.9
Pre- 2,507 3,200 21 1.060 0.851-1.320 0.606 R 49.32 0.000 59.4
Post- 10,243 14,548 26 0.969 0.915-1.025 0.271 F 32.47 0.271 23.0
PB 16,437 21,768 28 0.969 0.909-1.032 0.324 R 39.76 0.054 32.1
HB 4,973 8,203 20 1.060 0.902-1.245 0.478 R 48.71 0.000 61.0
FB 2,099 1,714 5 0.882 0.769-1.012 0.073 F 4.37 0.358 8.6
LL vs. HL+HH Overall 34,358 45,429 56 0.988 0.929-1.050 0.702 R 108.88 0.000 51.3
Caucasian 25,790 35,593 32 0.956 0.909-1.006 0.081 R 43.54 0.067 28.8
Asian 5,770 7,552 17 1.204 0.927-1.564 0.164 R 52.91 0.000 69.8
Pre- 3,903 4.800 21 1.053 0.855-1.297 0.627 R 49.44 0.000 59.5
Post- 13,969 19,581 26 0.980 0.901-1.065 0.629 R 37.85 0.048 33.9
PB 24,205 31,307 30 0.966 0.906-1.030 0.290 R 45.36 0.015 40.5
HB 7,262 11,750 20 1.098 0.934-1.289 0.257 R 54.38 0.000 65.1
FB 2,776 2,264 5 0.877 0.760-1.013 0.074 F 4.62 0.328 13.5
LL+HL vs. HH Overall 34,358 45,429 56 1.001 0.954-1.051 0.953 R 93.20 0.001 41.0
Caucasian 25,790 35,593 32 0.982 0.944-1.022 0.369 F 37.71 0.189 17.8
Asian 5,770 7,552 17 1.072 0.952-1.208 0.253 R 42.65 0.001 60.1
Pre- 3,933 4.839 22 1.016 0.890-1.160 0.815 R 33.81 0.038 37.9
Post- 14,001 19,604 27 1.001 0.924-1.084 0.987 R 40.17 0.038 35.3
PB 24,205 31,307 30 0.975 0.924-1.028 0.343 R 42.89 0.047 32.4
HB 7,262 11,750 20 1.091 0.978-1.216 0.118 R 39.26 0.004 51.6
FB 2,776 2,264 5 0.914 0.799-1.044 0.186 F 3.81 0.432 0.0
OR odds ratio, CI confidence intervals, R random effects model, F fixed effects model, PB Population-based study, HB Hospital-based study, FB Familial-based study,
Pre- Premenopausal, Post- Postmenopausal.
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alter the pattern of the results. Cumulative meta-analysis
was performed for dominant model LL +LH versus HH
in the overall populations. In the overall populations, therandom effects odds ratio was always insignificantly lar-
ger or smaller than 1. It changed little from around
0.998 after the year 2007 (Figure 3), indicating the stabil-
ity of the association.
Odds ratio
Decreased risk Increased risk
.115402  1 8.66534
Study
Odds ratio
(95% CI)      % Weight
Lavigne (1997) 0.46 ( 0.12, 1.85)  0.9 
Thompson (1998) 2.25 ( 1.31, 3.88)  4.2 
Millikan (1998) 0.78 ( 0.56, 1.09)  7.4 
Huang (1999) 0.97 ( 0.43, 2.15)  2.3 
Mitrunen (2001) 0.69 ( 0.43, 1.13)  4.9 
Yim (2001) 1.73 ( 0.95, 3.13)  3.7 
Bergman-Jungestrom (2001) 0.86 ( 0.39, 1.87)  2.4 
Hamajima (2001) 1.41 ( 0.75, 2.66)  3.4 
Kocabas (2002) 1.97 ( 0.75, 5.18)  1.7 
Tan (2003) 1.18 ( 0.67, 2.08)  4.0 
Sazci (2004) 1.12 ( 0.69, 1.84)  4.8 
Wen (2005) 0.92 ( 0.75, 1.13)10.7 
Onay (2006) 0.80 ( 0.57, 1.11)  7.5 
Gaudet 1 (2006) 0.92 ( 0.65, 1.29)  7.4 
Ralph 1 (2007) 0.86 ( 0.68, 1.11)  9.6 
Ralph 2 (2007) 1.24 ( 0.81, 1.88)  5.9 
Hu (2007) 1.25 ( 0.65, 2.39)  3.2 
Yadav (2009) 0.75 ( 0.38, 1.46)  3.1 
Moreno-Galván (2010) 0.87 ( 0.33, 2.28)  1.7 
Wang (2011) 1.09 ( 0.75, 1.58)  6.7 
Lajin (2011) 0.67 ( 0.35, 1.29)  3.2 
Santos (2011) 3.20 ( 1.18, 8.67)  1.6 
Overall 1.02 ( 0.89, 1.16)100.0 
Figure 1 OR and 95% CI of individual studies and pooled data for the association between the COMT Val158Met polymorphism and
BC in premenopausal populations using a random-effect model (dominant model LL+HL vs. HH).
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Begg’s funnel plots and Egger’s tests were performed to
assess publication bias. The shapes of the funnel plots
revealed no obvious asymmetry (Figure 4). The Egger’s
































Figure 2 OR and 95% CI of individual studies and pooled data for the
BC in postmenopausal populations using a random-effect model (domsymmetry. The results suggested no evidence of publica-
tion bias (t = 0.94 and P = 0.352 for dominant model).
The results indicated that the results of these meta-
analyses are relatively stable and that publication bias is
unlikely to affect the results of the meta-analyses.ncreased risk
10
Odds ratio
(95% CI) % Weight
1.87 ( 0.89, 3.92)  1.1 
0.58 ( 0.34, 0.99)  1.9 
0.82 ( 0.59, 1.13)  4.3 
0.68 ( 0.34, 1.33)  1.3 
0.93 ( 0.63, 1.38)  3.2 
1.56 ( 0.81, 3.02)  1.3 
1.30 ( 0.69, 2.45)  1.4 
0.60 ( 0.26, 1.36)  0.9 
0.29 ( 0.15, 0.54)  1.5 
1.02 ( 0.85, 1.22)  8.2 
1.20 ( 0.77, 1.88)  2.6 
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Figure 3 Cumulative meta-analysis of the association between COMT Val158Met polymorphism and breast cancer susceptibility risk of
the overall populations using a random effects model (dominant model LL+HL versus HH). Each study was used as an information step.
The vertical dotted line is the summary odds ratio. Bars, 95% confidence interval (CI).
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Estrogens, estrone, and estradiol are catabolized to cat-
echol estrogens. Estrogen metabolites, such as 4-
hydroxyestrone and 4-hydroxyestrone, shown to be
involved in breast carcinogenesis [74]. Catechol-O-
methyltransferase (COMT) catalyzes the O-methylation








Figure 4 Funnel plots for publication bias in the studies of the meta-
polymorphism and breast cancer risk of the overall populations (domand methoxyestrones. In the COMT gene, a G to A tran-
sition results in an amino acid change (Val/Met) at
codon 108 of soluble COMT and codon 158 of
membrane-bound COMT. This amino acid change is
believed to result in a 3–4-fold decrease in enzymatic ac-
tivity [6,7]. It has been hypothesized that individuals
who inherit the low activity COMT gene may be atof: logor
.2 .4
analysis on the association between COMT Val158Met
inant LL+HL versus HH).
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accumulation of the catechol estrogen intermediates.
The potential association between the COMT Val108/
158Met polymorphism and the risk of subsequent BC
has evoked a huge interest from clinicians, scientists,
and the public. During the past few years a large number
of studies with case–control design have been carried
out to investigate this topic but consistent results have
not been reported. We therefore conducted a meta-
analysis of the evidence obtained from all published
studies in order to elucidate and provide a quantitative
reassessment of the association. To our knowledge, this
is the most comprehensive meta-analysis to date to
evaluate the association between COMT Val108/158Met
polymorphism and breast cancer risk.
We did not observe a positive relationship between
COMT Val108/158Met polymorphism and breast cancer
risk either overall or among subgroups of women
defined by ethnicity, menopausal status or sources of the
control population. In previous studies, overall the find-
ings were inconsistent. Lavigne et al. observed a large
increase in the risk of breast cancer among postmeno-
pausal obese women carrying the COMT-LL genotype,
and an inverse association among premenopausal
women with the relative risk (RR) for COMT-LL stron-
ger among postmenopausal women with high BMI [9].
Thompson et al. reported positive associations for the
COMT-HL and COMT-LL genotypes among premeno-
pausal women and found that modification of RRs by
BMI was highest among premenopausal women with a
high BMI [10]. A comprehensive study of the entire
estrogen-metabolizing pathway (CYP17, CYP1A1,
COMT) also reported that breast cancer is only asso-
ciated with the low activity COMT genotype in women
with a high BMI and that the COMT-LL genotype was
strongly associated with breast cancer risk, with an
adjusted OR of as high as 4.02 [12]. In contrast to the
other studies but in line with the findings of the current
study, Lajin et al. did not observe any association be-
tween one or two copies of the COMT-L allele and
breast cancer risk, and did not find strong modification
of RR estimates by menopausal status [72]. In an effort
to shed some light on the impact of COMT Val108/
158Met polymorphism on breast cancer risk, two previ-
ous meta-analyses [17,18] were conducted almost at the
same time to explore the relationship between COMT
Val108/158Met polymorphism and breast cancer. Ding
et al. [18] examined the effect of COMT Val158Met
polymorphism on breast cancer risk by combining
results in meta-analysis. They concluded that COMT
Val158Met polymorphism was significantly associated
with increased breast cancer risk in European popula-
tion. However, Mao et al. [17] did not find any relation-
ship between COMT Val158Met polymorphism andbreast cancer risk in any genetic models including
among Caucasian, Asian, premenopausal, and postmeno-
pausal women in their meta-analysis, which was consistent
with the findings of our study. The discrepancy in previ-
ously reported findings was most probably because that the
previous studies with relatively small sample size may have
insufficient statistical power to detect the exact effect or
may have generated a fluctuated risk estimate. However, in
our study, large number of cases and controls were pooled
from all published studies, which greatly increased statis-
tical power of the analysis and provided enough evidence
for us to draw a safe and reliable conclusion.
Heterogeneity is a potential problem that may affect
the interpretation of the results. The present meta-
analysis showed that there was large heterogeneity be-
tween studies (table 2). Common reasons for heterogen-
eity may include differences in the studied populations
(e.g., ethnicity, menopausal status), or in methods (e.g.,
genotyping), or in sample selection (e.g., source of con-
trol populations), or it may be due to interaction with
other risk factors (e.g., BRCA variants). Finding of the
source of heterogeneity is one of the most important
goals of a meta-analysis. Therefore, we stratified the
studies according to ethnicity, source of control subjects
of the studies, and menopausal status. Subsequent sub-
group analysis stratified by ethnicity, source of control
subjects, and menopausal status identified large hetero-
geneity as well, indicating that menopausal status, ethni-
city or source of control subjects contributed little to the
existence of overall heterogeneity. Unfortunately, our
study had insufficient information for subgroup analysis
to detect whether the variants in BRCA gene might be
great sources of heterogeneity. We found that in three
studies [33,41,70] the genotypic frequencies showed sig-
nificant deviation from the expected frequencies based
on Hardy–Weinberg equilibrium and two studies [66,73]
provide insufficient data for calculating P value of HWE
in the control populations. Excluding these five studies
did not alter the heterogeneity between studies. How-
ever, when heterogeneity between the studies exists, the
results could be interpreted in the context of cumulative
meta-analysis, which provides a measure of how much
the genetic effect changes as more data accumulate over
time [75]. In our study, the results of cumulative meta-
analysis for dominant model LL+HL versus HH showed
stability in pooled odds ratio after the year 2007 in the
overall populations, which provide evidence for drawing
safe conclusion about the insignificant association be-
tween COMT Val158Met polymorphism and breast can-
cer risk.
Some limitations of this meta-analysis should be
acknowledged. First, some studies found significant asso-
ciations between COMT Val108/158Met polymorphism
and breast cancer risk in several subgroups of
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sal women with a low body mass index (BMI) [10,11], a
high BMI [9] or women at young ages [11]. It is difficult
for a meta-anlysis to derive such specific associations be-
cause the results from previous studies were not pre-
sented in a uniform standard. Second, our results were
based on unadjusted estimates and a more precise ana-
lysis should be carried out if individual data were avail-
able, this would allow for adjustment by other covariates
including age, BMI, ethnicity, lifestyle, and environmen-
tal factors. Third, all of the studies were performed in
Asian and Caucasian populations. Further studies are
needed in other ethnic populations because of possible
ethnic differences of the COMT polymorphisms. In spite
of these, our present meta-analysis also had some advan-
tages. First, substantial number of cases and controls
were pooled from all publications concerned with
COMT Val158Met polymorphism and BC risk, which
greatly increased statistical power of the analysis and
provided enough evidence for us to draw a safe conclu-
sion. Second, the quality of case–control studies
included in this meta-analysis was satisfactory according
to our selection criteria. Third, no publication bias was
detected in this meta-analysis, which indicated that the
pooled results of our study should be reliable.
In conclusion, this meta-analysis suggests that the
COMT Val158Met polymorphism may not be associated
with breast cancer risk. However, it is necessary to con-
duct large sample studies using standardized unbiased
genotyping methods, homogeneous breast cancer
patients, and well-matched controls. Moreover, gene-
gene and gene-environment interactions should also be
considered in the analysis. Such studies taking these fac-
tors into account may eventually lead to a better, more
comprehensive understanding of the association between
COMT Val158Met polymorphism and BC risk.
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